Buscar
Results for 'lab'
Clear-
Gilead Sciences y el Renown Institute for Health Innovation anuncian una colaboración estratégica para promover la comprensión de la esteatohepatitis no alcohólica (EHNA)
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. En virtud de los términos del acuerdo de colaboración y licencia, Gilead proporcionará fondos al Renown IHI para secuenciar y analizar el ADN de 15,000 personas que viven con EHNA o con enfermedad de hígado graso no alcohólico (EHGNA), así como de una cohorte de control de 40,000 personas en el estado de Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene 40,000 participantes. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.” About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. La EHNA es más frecuente en personas con ciertas afecciones, que incluyen obesidad y diabetes tipo 2. There are currently limited approved treatments for patients living with NASH. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead opera en más de 35 países alrededor del mundo, con sede central en Foster City, California. Para obtener más información sobre Gilead Sciences, visite el sitio web de la empresa en www.gilead.com. About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org. About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Mediante el uso de su ensayo Exome+™ de propiedad exclusiva, un exoma de tipo panel mejorado con más de 300,000 regiones no codificantes informativas, Helix ofrece a los sistemas de salud una solución escalable que permite el descubrimiento de información genética médicamente relevante y que potencialmente puede salvar vidas. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Obtenga más información en www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC. Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Estos y otros riesgos se describen en detalle en el Informe Trimestral de Gilead en el Formulario 10-Q para el trimestre que finalizó el 31 de marzo de 2019, presentado ante la Comisión de Bolsa y Valores de los EE. UU. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Additional Media Contact: Sung Lee, Investors 650-524-7792 Arran Attridge, Media 650-425-8975
-
Los exámenes de detección genética poblacionales demuestran que identifican de manera eficiente un aumento en el riesgo de padecer enfermedades hereditarias
El enfoque basado en la comunidad del Healthy Nevada Project revela que hasta un 90 % de los riesgos de padecer afecciones genéticas de Nivel 1 de los CDC no se detecta cuando se usan pautas de atención clínica. In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke. En 2018, el Healthy Nevada Project® (el mayor estudio de salud poblacional basado en la comunidad que combina datos genéticos, clínicos, ambientales y sociales) comenzó a notificarles a los participantes del estudio que habían dado su consentimiento sobre ciertas variantes genéticas que los predisponían a padecer las afecciones genéticas de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). The study focused on identifying carriers of these conditions, which include Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia, because they are the most common conditions and early detection and treatment could significantly lower morbidity and mortality. Los resultados iniciales de casi 27,000 participantes del estudio mostraron que el 90 % de los portadores de las afecciones genéticas de Nivel 1 de los CDC no había sido previamente identificado en un entorno clínico. The authors conclude that population genetic screening would identify at-risk carriers not identified during routine care. “Our first goal was to deliver actionable health data back to the participants of the study and understand whether or not broad population screening of CDC Tier 1 genomic conditions was a practical tool to identify at-risk individuals,” explained Joseph Grzymski, Ph.D., the principal investigator of the Healthy Nevada Project®, a research professor at the Desert Research Institute (DRI), chief scientific officer for Renown Health and lead author of the study. “Now, two years into doing that, it is clear that the clinical guidelines for detecting risk in individuals are too narrow and miss too many at risk individuals.” Del grupo de 26,906 participantes del Healthy Nevada Project® que el equipo de investigación de Grzymski estudió, 358 (el 1.33 %) eran portadores de afecciones de Nivel 1 de los CDC. Sin embargo, solo el 25 % de esas personas cumplían las pautas clínicas para realizarse exámenes de detección genética. Además, más del 20 % de los portadores ya tenía un diagnóstico de enfermedad relacionada con la afección genética subyacente. “We’re at a point now where it’s possible to do clinical-grade genetic screening at population-scale,” added James Lu, M.D. Ph.D., co-founder and chief scientific officer of Helix and senior co-author of the study. “What this study demonstrates is the potential impact of doing so. By making genetic screening available more broadly, we can help the millions of Americans who are unaware that they are living at increased risk for highly actionable, genetic conditions take action.” En particular, el estudio descubrió que de los 273 participantes que eran portadores de las afecciones genéticas de Nivel 1 de los CDC y que tenían información de registros clínicos, solo 22 personas mostraron sospechas previas de tener estas afecciones genéticas subyacentes. “For the first time, we are providing information at the individual level so study participants can make lifesaving changes to reduce their risk based on their genetics,” said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-director of the Project® study. “We’re conducting research on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country. Returning these results allows us to understand the prevalence of genetically programmed diseases and illnesses that we have here in Nevada and ensure we are providing the best prevention and care plans. For the individual, the return of results can be life changing.” According to the CDC, early detection and intervention of the Tier 1 genetic conditions could have a meaningful potential for clinical action ability and a positive impact on public health. El Healthy Nevada Project®, que se lanzó en 2016, ofrece pruebas genéticas gratuitas a todos los residentes de Nevada, mayores de 18 años, interesados en obtener más información sobre su salud y perfil genético. Con más de 50,000 participantes del estudio inscritos en cuatro años, el Healthy Nevada Project® se ha convertido en el estudio genético de más rápida inscripción del mundo. For more about the Healthy Nevada Project® please visit healthynv.org Renown Institute for Health Innovation is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at Healthynv.org. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+Ⓡ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country. Obtenga más información en www.helix.com.
-
Departamento destacado: Oncología médica
The month of September recognizes several cancer-related health observances. Join us in celebrating our Medical Oncology team at Renown! No person ever wants to hear the words, “You have cancer.” Those three short yet impactful words immediately change the course of someone’s life. As these patients Fight the Good Fight against cancer, there are a lot of intimidating unknowns that can take over their minds. What happens next? What will my treatment be like? What is my prognosis? How will I be able to handle this physically and emotionally? What will it take for me to beat this? Who is better to be by their side than the devoted team members at the William N. Pennington Cancer Institute at Renown Health? From helping patients manage the process of complex paperwork and referrals to delivering personalized oncology and hematology treatment options tailored to each individual diagnosis, those fighting virtually any type of cancer are never alone, thanks to this team. The William N. Pennington Cancer Institute always lives up to that promise, guiding patients through the daunting journey of cancer treatment ahead, one step at a time. Courageous Against Cancer Our exceptional Medical Oncology department inherently understands that each moment in life is precious, especially for patients battling cancer. This team is dedicated to orchestrating the most comprehensive plan for each patient, seamlessly weaving together diagnoses and treatments, oral chemotherapy, medication management, clinical trials, radiation oncology and more. With the many patients they impact, there’s no question that there is never a dull moment in the day of the life of a healing hero like those in this department. “No day is the same in Medical Oncology,” said Hollyann Dehm, Registered Nurse. “As a nurse, we wear many hats in the clinic. Our role is to educate patients on their treatment plans and specific drugs they are receiving, triage symptom calls from patients, refill medications and implement our oral chemotherapy program. We help provide direct patient care by accessing ports, drawing labs and giving IV hydration when needed. We also help fill out family and medical leave (FMLA)/disability paperwork, help with physician orders, help obtain prior authorizations for prescribed medications and treatments.” “We do our best to let our patients know that they will not be going through this alone,” added Danielle Say, Physician Scheduling Coordinator. "We will be here for them every step of the way, guiding them and making sure their treatment is as smooth as possible and making ourselves available to them as much as we can. We end up getting to know many of our patients on a very close, personal level, and this helps to build that trust.” “Our day-to-day activities include seeing patients and helping to manage their therapies as well as their toxicities,” added Dr. Harry Menon, DO, Oncology Physician. “We work closely with our infusion room staff and have a robust team to help us deal with these complex patients. We also work very closely with our surgical and radiation oncology colleagues in a multidisciplinary fashion to provide comprehensive care for our patients.” The Medical Oncology team excels not only in providing cutting-edge cancer care but also in their compassionate approach to helping patients reduce the anxieties they understandably feel. Recognizing that a cancer diagnosis can be an emotionally overwhelming experience, this dedicated team combines medical expertise with unwavering support to create a healing environment. “When patients are referred to our department, a lot of them have many fears and questions,” said Heather Cortez, Medical Assistant. “A majority of what our team does is focused on the mental support that our patients require to help them have the most successful outcomes. One thing I have learned about cancer care is that positivity in the face of adversity is everything. Just being there to listen to our patient’s concerns can make all the difference. Helping them to navigate their many appointments and taking the time to explain things in a patient and compassionate way, is part of how our team serves this vulnerable population.” “The uncertainty is one of my patients' biggest fears: How far has my cancer progressed? How long will I have left? Is treatment even an option?” added Mary Wilson, Senior Medical Assistant. “The best advice that I can give my patients is that they are not alone. While this battle is going to be one of the hardest parts of their lives, they are surrounded by constant support to try and help with any burdens they may be facing. I also tell my patients that we have to take the little wins no matter how small they may be, because while cancer treatment is a physical battle, it is also a large mental battle." “While we don’t have answers to all the questions patients and their family members may have, we do our best to listen to their questions and concerns regarding their cancer diagnosis and treatment and guide them through their cancer journey," added Hollyann Dehm. “We provide emotional support and education on their type of cancer, managing their pain and side effects of their treatment. We also connect them to nurse navigators and our social worker who also help identify barriers to care and provide the patient with resources.” Whether it's explaining treatment options in understandable terms or offering emotional support through difficult moments, this department is committed to empowering patients on their journey toward healing. Their holistic approach not only treats the disease but also nurtures the spirit, all while being a strong advocate on each patient’s behalf. “Getting a cancer diagnosis can be the worst news that a person can hear; what we try to do is focus on improving quality life and focus on goals that help to promote quality of life,” said Dr. Harry Menon. “If the option for a cure is on the table, we try and focus on that goal in concert with promoting quality life. I try and have our patients focus on what they can control, with the understanding that even if some things are out of our control, the way we approach and manage those things, including our mindset, is still within our control.” “In our clinic, we truly value our patients and how they are cared for,” added Mary Wilson. “The amount of compassion our team shows is incredible. Patients constantly commend our team on how much they feel like the provider's care. Our providers and staff are not afraid to advocate for patients and that truly is an accomplishment in and of itself.” “We know patients are only hearing a small amount of the immense volume of information we provide them, so we encourage them to ask questions until it makes sense because the timeframe is different for every patient,” said Lillian Morton, APRN of Medical Oncology. “Cancer is an anxiety inducing lack of control whirlwind – if we can help by being responsive to patient calls and messages, we do so.” With their harmonious and integrated approach, each patient’s treatment journey progresses uninterrupted, bringing them closer to a brighter and healthier future.